AXL signalingsuppresses proinflammatory Toll-like receptor (TLR) responses in antigen-presentingcells (APCs).7 During apoptotic cell ingestion,MER suppresses the M1 macrophage proinflammatory cytokine responseand enhances M2 macrophage anti-inflammatory cytokine production.8 Recent preclinical studies demonstrated thatMER mediates intrinsic and adaptive resistance to AXL-targeting agentsin human head and neck squamous cell carcinoma (HNSCC), triple-negativebreast cancer (TNBC), and non-small cell lung cancer (NSCLC). The gene discussed is MERTK; the disease is non-small cell lung carcinoma.